Codexis strikes technology deal with Merck; Unichem pill mix-up leads to recall;

> Unichem Pharmaceuticals is voluntarily recalling one lot of hydrochlorothiazide blood pressure medication after a clopidogrel blood thinner tablet was found in a bottle. Notice

> Codexis ($CDXS) has licensed its biocatalyst enzyme development technology to Merck ($MRK) in a deal that could earn it up to $18 million. Release

> India's Drug Control Administration (DCA) has served show cause notices on 24 pharmaceutical companies in Hyderabad, two of which had their manufacturing units seized. Story

> Pharma chemical producer Caesar & Loretz (Caelo) is investing more than €10 million ($10.97 million) to modernize and expand its production, warehousing and headquarters in Hilden, Germany. Report

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.